Augmenting Flortaucipir Dosimetry Estimates

Avid Radiopharmaceuticals6 enrolled

Overview

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Alzheimer's Disease

Interventions

Flortaucipir F18DRUG

No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who passed screening in an Avid-sponsored study in which flortaucipir will be administered Exclusion Criteria: * Subjects who have withdrawn informed consent * Investigator or sponsor believes it is in the best interest of the subject to be removed from the trials

Locations (1)

Molecular NeuroImaging

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

Urine Analysis - Total Integrated Radioactivity Excreted in Urine

Total integrated radioactivity excreted in urine over time will be determined to augment previous radiation dosimetry calculations.

Time frame: 0-360 minutes post injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.